When was myTomorrows founded?

myTomorrows was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is myTomorrows located?

myTomorrows is headquartered in Amsterdam, Netherlands.

Who is the current CEO of myTomorrows?

Ronald Brus of myTomorrows. They have also founded 1 company.

How many employees does myTomorrows have?

As of Aug 31, 2026, the latest employee count at myTomorrows is 152.

Is myTomorrows a funded company?

myTomorrows is a funded company, having raised a total of $51.3M across 5 funding rounds to date. The company's 1st funding round was a $***** Angel round, raised on 2012.

When was the latest funding round of myTomorrows?

myTomorrows' latest funding was a $***** Series C round on Nov 11, 2025, with participation from 1 investor.

Where does myTomorrows rank among its competitors?

myTomorrows ranks 10th amongst 1420 active competitors, of which 344 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Tempus, which secured $460M in Jul, 2026.

Who are the top competitors of myTomorrows?

myTomorrows' top competitors include Verily, IQVIA and Innovaccer. Among them, Tempus secured the most recent funding round in July, 2026.

myTomorrows - 2026 Company Profile, Team, Funding & Competitors

myTomorrows is a series C company based in Amsterdam (Netherlands), founded in 2012 by Ronald Brus, Govert Schouten and Erdem Yavuz. It operates as a Platform provides access to drugs in development to patients and physicians. myTomorrows has raised $51.3M in funding from investors like Balderton Capital, Sofinnova Investments and Octopus Ventures. The company has 1420 active competitors, including 344 funded and 184 that have exited. Its top competitors include companies like Verily, IQVIA and Innovaccer.

Company Details

myTomorrows offers a platform for early drug access to patients and doctors. The platform connects patients, doctors, and drug companies. It provides information on medical conditions, related clinical trials, and early access programs through its platform. The platform facilitates requests for drugs in development and supplies diagnostic tests.

Website: mytomorrows.com
Social
Email ID: *****@mytomorrows.com
Phone Number: +31 **********

Key Metrics

Founded Year

2012

Location

Amsterdam, Netherlands

Stage

Series C

Total Funding

$51.3M in 5 rounds

Latest Funding Round

Series C, Nov 11, 2025, $*****

Investors

Balderton Capital & 6 more

Ranked

10^th among 1420 active competitors

Employee Count

152 as on Aug 31, 2026

Similar Companies

Evidation & 242 more

View myTomorrows' full profile

myTomorrows has raised a total funding of $51.3M over 5 rounds. Its first funding round was on 2012. Its latest funding round was a Series C round on Nov 11, 2025 for $*****. 1 investor participated in its latest round. myTomorrows has 7 institutional investors.

Here is the list of recent funding rounds of myTomorrows:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 11, 2025	9084323	Series C	3954355	1723369	1253703	3336132
Jan 09, 2017	9945869	Series B	7212997	2769877	1503342	Balderton Capital & 1 more
Nov 07, 2014	3491241	Series A	5683792	9073618	Balderton Capital & 1 more	2623878

Access funding benchmarks and valuations. Sign up today!

View details of myTomorrows's funding rounds and investors

The founders of myTomorrows are Ronald Brus, Govert Schouten and Erdem Yavuz. Ronald Brus is the CEO of myTomorrows.

Here are the details of myTomorrows' key team members:

Ronald Brus: Co-Founder & CEO of myTomorrows and founder of 1 other company.
Contact Info: 1 email address
Govert Schouten: Former Co-Founder of myTomorrows and founder of 1 other company.
Contact Info: 1 email address
Erdem Yavuz: Former Co-Founder of myTomorrows.

View details of myTomorrows's Founder profiles and Board Members

myTomorrows' employee count trend

myTomorrows has 152 employees as of Aug 26. Here is myTomorrows's employee count trend over the years:

Uncover myTomorrows' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of myTomorrows include Verily, IQVIA and Innovaccer. Here is the list of Top 10 competitors of myTomorrows, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Verily 2015, Dallas (United States), Series D	A data platform and technology company purpose-built to power AI-enabled precision health	$2.8B	Silver Lake, Temasek & 9 others	82/100
2nd	IQVIA 1982, Durham (United States), Public	Provider of clinical research and commercialization solutions for healthcare	$1.74M	Leonard Green and Partners, Aisling Capital ... & 12 others	80/100
3rd	Innovaccer 2014, San Francisco (United States), Series F	Developer of healthcare data platforms and artificial intelligence agent software	$675M	WestBridge Capital, Mubadala & 36 others	78/100
4th	Tempus 2015, Chicago (United States), Public	Developer of genomic testing and artificial intelligence tools for medicine	$1.05B	T. Rowe Price, New Enterprise Associates ... & 11 others	77/100
5th	Manifold AI 2016, Oakland (United States), Series B	Provider of an AI platform for life sciences research and development	$40M	TQ Ventures, Reach Capital & 13 others	72/100
6th	Evidation 2012, Menlo Park (United States), Series E	Real-world health data insights for better healthcare decisions and research	$259M	B Capital, Sanofi Ventures & 16 others	70/100
7th	Hyro 2014, New York City (United States), Series C	Provider of an AI-based conversational platform	$115M	Healthier Capital, Spider Capital & 16 others	70/100
8th	Inspiren 2016, Brooklyn (United States), Series B	AI based patient monitoring system for healthcare professionals	$155M	Avenir Growth Capital, Insight Partners & 7 others	69/100
9th	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Walden Catalyst, EDBI & 23 others	68/100
10th	myTomorrows 2012, Amsterdam (Netherlands), Series C	Platform provides access to drugs in development to patients and physicians	$51.3M	Kreos Capital, EQT & 5 others	67/100